CraniUS Therapeutics offers an implantable drug delivery system that bypasses the blood-brain barrier for targeted treatment of brain diseases. The NeuroPASS™ device enables precise, localized administration of medication directly to affected brain regions, maximizing therapeutic efficacy and minimizing systemic side effects.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Treating aggressive brain tumors and neurodegenerative diseases is challenging due to the blood-brain barrier, which restricts the passage of therapeutic agents to the central nervous system. Conventional systemic drug delivery methods often result in significant off-target effects and limited efficacy within the brain parenchyma.
Solution
CraniUS Therapeutics has developed the NeuroPASS™, a novel, skull-implantable drug delivery system designed to circumvent the blood-brain barrier. This implantable device facilitates the direct, targeted delivery of microdoses of medication to specific regions of the brain, such as tumors or affected tissues. By creating a localized concentration gradient, NeuroPASS™ aims to maximize therapeutic impact while minimizing systemic exposure and associated adverse events. The system's MRI-compatible design ensures it can be safely used in conjunction with advanced neuroimaging modalities for treatment monitoring.
Target Audience
The primary target audience includes neurosurgeons, oncologists, neurologists, and pharmaceutical companies developing therapies for central nervous system disorders.
Features
- Skull-implantable convection-enhanced delivery (CED) device for direct intracranial drug administration.
- Bypasses the blood-brain barrier to achieve targeted therapeutic concentrations within brain tissue.
- Delivers precise microdoses of medication via a controlled flow rate, forming a localized distribution cloud.
- Designed to reduce systemic side effects commonly associated with traditional chemotherapy or neuropharmaceuticals.
- Fully implantable within the skull, offering a virtually invisible profile with no visible cranial deformity.
- MRI-compatible engineering to minimize image artifacting during diagnostic scans.
- Potential application for aggressive brain tumors, Alzheimer's disease, and Parkinson's disease.